PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
October 16, 2025Thoracic CancerOpen Access

The Progression Patterns and Subsequent Treatments of First‐Line Immunotherapy in Advanced Non‐Small Cell Lung Cancer: A Retrospective Cohort Study

View Full Paper
Ask AI
Bookmark
Share

Authors

QHQi HeXGXiaobei GuoYCYun-Fei Chen

Discussion

Loading...

Member takes

Overview

Retrospective cohort study reveals progression patterns and survival outcomes in non-small cell lung cancer, suggesting treatment implications.

Key Points

  • Systemic progression occurred in 67.5% of metastatic non-small cell lung cancer patients treated with immunotherapy.
  • Median post-progression survival was significantly better in patients with oligoprogression compared to those with systemic progression.
  • Immunotherapy, or ICI-containing regimens, resulted in a median survival benefit of 29.0 months over 11.3 months in regimens without ICIs.
  • Extrapulmonary progression indicated poorer survival rates compared to isolated lesion progression.

Cite This Study

He et al. (2025) studied this question.

synapsesocial.com/papers/68f147cc724575985c3fd333https://doi.org/10.1111/1759-7714.70173
View Full Paper
Ask AI
Bookmark
Share